Conatumumab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Human |
| Target | TRAIL-R2 (CD262) |
| Clinical data | |
| ATC code | none |
| Identifiers | |
| Synonyms | anti-TRAIL receptor 2 monoclonal antibody, AMG 655 |
| CAS Number |
896731-82-1  |
| ChemSpider | none |
| UNII |
1P48L61KM0  |
| KEGG |
D09329 |
| Chemical and physical data | |
| Formula | C6466H10006N1730O2024S40 |
| Molar mass | 145.65 kg/mol |
| (what is this?) (verify) | |
Conatumumab (originally AMG 655) is a monoclonal antibody developed for the treatment of cancer. it is a fully human monoclonal agonist antibody directed against the extracellular domain of human TRAIL (tumor necrosis factor-related apoptosis-inducing ligand) receptor 2 (TR-2, death receptor 5) with potential antineoplastic activity. Conatumumab mimics the activity of native TRAIL, binding to and activating TR-2, thereby activating caspase cascades and inducing tumor cell apoptosis. TR-2 is expressed by a variety of solid tumors and cancers of hematopoietic origin.[1][2]
The drug was developed by Amgen Inc.
Clinical trials
It will be included in the forthcoming I-SPY2 breast cancer trial.[3]
References
- ↑ Statement On A Nonproprietary Name Adopted By The USAN Council – Conatumumab, American Medical Association.
- ↑ National Cancer Institute: Definition of conatumomab
- ↑ http://www.reuters.com/article/idUSN1612347120100317 "Breast cancer study aims to speed drugs, cooperation" March 2010
This article is issued from Wikipedia - version of the 9/12/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.